OmniTopics Harmony Hub

.Bristol Myers Squibb is axing another major bet from the Caforio era, ending an offer for Agenus’ TIGIT bispecific antibody 3 years after paying for

.Bristol Myers Squibb has actually possessed a whiplash change of mind on its own BCMA bispecific T-cell engager, stopping (PDF) further growth months after submitting

.AvenCell Rehabs has gotten $112 million in collection B funds as the Novo Holdings-backed biotech looks for scientific evidence that it can produce CAR-T cells

.Atea Pharmaceuticals’ antiviral has failed another COVID-19 test, however the biotech still keeps out really hope the candidate has a future in hepatitis C.The dental

.Pinetree Therapies are going to assist AstraZeneca plant some trees in its own pipe along with a brand-new pact to cultivate a preclinical EGFR degrader

.AstraZeneca has settled CSPC Drug Team $100 million for a preclinical heart attack medication. The bargain, which covers a possible competitor to an Eli Lilly

.AstraZeneca has discussed a very early check out the efficiency of its own internal antibody-drug conjugate (ADC) innovation, releasing stage 1 data on applicants that

.AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has neglected to improve general survival (OS) in non-small tissue lung cancer cells (NSCLC), expanding the listing

.AstraZeneca executives mention they are “certainly not concerned” that the failure of tozorakimab in a period 2 persistent obstructive lung disease (COPD) trial are going

.Ascendis Pharma has actually emerged as a potential threat to BioMarin’s Voxzogo, reporting period 3 growth ailment data that went beyond expert assumptions and also